ClinicalTrials.Veeva

Menu

(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors

C

Cogent Biosciences

Status and phase

Enrolling
Phase 3

Conditions

Metastatic Cancer
Advanced Gastrointestinal Stromal Tumors

Treatments

Drug: Bezuclastinib
Drug: Bezuclastinib
Drug: Sunitinib
Drug: Midazolam
Drug: Bezuclastinib
Drug: Bezuclastinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT05208047
CGT9486-21-301

Details and patient eligibility

About

This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).

Enrollment

482 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  1. Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization. (GIST 1L Substudy: must have documented mutation in KIT Exon 9 with an available molecular pathology report; archival or fresh tumor tissue sample will be required)

  2. Documented disease progression on or intolerance to imatinib (Part 1a, Part 1b, Part 2, DDI Substudy)

  3. Participants must have received the following treatment:

    • DDI Substudy/Part 1a: Treatment with ≥1 prior lines of therapy for GIST
    • Part 1b: Treatment with ≥2 prior TKI for GISTs
    • Part 2: Prior treatment with imatinib only
    • GIST 1L Substudy: No prior systemic therapy for GIST including adjuvant therapy. Exception: up to 10 participants with ongoing imatinib therapy of ≤4 weeks
  4. Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part 2, GIST 1L Substudy)

  5. Eastern Cooperative Oncology Group (ECOG) Status

    • 0 to 2 (Part 1a, Part 1b, Part 2, DDI Substudy)
    • 0 to 1 (GIST 1L Substudy)
  6. Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits

Key Exclusion Criteria:

  1. Known Platelet-Derived Growth Factor Receptor (PDGFR) driving mutations or known succinate dehydrogenase deficiency (Part 1a, Part 1b, Part 2, DDI Substudy)
  2. Clinically significant cardiac disease
  3. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug (Part 1a, Part 1b, Part 2, DDI Substudy)
  4. Gastrointestinal abnormalities including, but not limited to, significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption
  5. Any active bleeding excluding hemorrhoidal or gum bleeding
  6. Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody.
  7. Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening
  8. Received strong CYP3A4 inhibitors or inducers (Part 1a, Part 1b, Part 2, DDI Substudy)
  9. Received sunitinib within 3 weeks (Part 1a, Part 1b, DDI Substudy)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

482 participants in 7 patient groups

Part 1a
Experimental group
Description:
Bezuclastinib plus sunitinib 37.5 mg once a day (QD)
Treatment:
Drug: Bezuclastinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Bezuclastinib
Drug: Bezuclastinib
Drug: Bezuclastinib
Part 2 - Experimental Group
Experimental group
Description:
Bezuclastinib plus sunitinib 37.5 mg QD
Treatment:
Drug: Bezuclastinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Bezuclastinib
Drug: Bezuclastinib
Drug: Bezuclastinib
Part 2 - Control Group
Active Comparator group
Description:
Sunitinib 37.5 mg QD
Treatment:
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Part 1b - DDI Cohort 1
Experimental group
Description:
Bezuclastinib plus sunitinib 37.5 mg QD
Treatment:
Drug: Bezuclastinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Bezuclastinib
Drug: Bezuclastinib
Drug: Bezuclastinib
Part 1b - DDI Cohort 2
Experimental group
Description:
Sunitinib 37.5 mg QD plus bezuclastinib
Treatment:
Drug: Bezuclastinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Bezuclastinib
Drug: Bezuclastinib
Drug: Bezuclastinib
DDI Substudy (Midazolam)
Experimental group
Description:
Midazolam, bezuclastinib, sunitinib
Treatment:
Drug: Bezuclastinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Midazolam
Drug: Sunitinib
Drug: Sunitinib
Drug: Bezuclastinib
Drug: Bezuclastinib
Drug: Bezuclastinib
GIST 1L Substudy
Experimental group
Description:
Bezuclastinib, sunitinib
Treatment:
Drug: Bezuclastinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Sunitinib
Drug: Bezuclastinib
Drug: Bezuclastinib
Drug: Bezuclastinib

Trial contacts and locations

127

Loading...

Central trial contact

Cogent Biosciences

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems